Meningitis is an inflammation (swelling)
of the defensive layers called meninges covering the brain and spinal
cord. A bacterial or viral contamination of the fluid encompassing the
brain and spinal cord ordinarily causes the swelling. However, wounds,
disease, certain medications, and different kinds of infections can also
cause meningitis. Bacterial meningitis is intense and can be mortal.
Additionally, bacterial meningitis can cause permanent disabilities such
as brain damage and hearing loss, if untreated. However, the vast
majority of meningitis can prevent with proper vaccination.
Streptococcus pneumonia, neisseria meningitides, and listeria
monocytogenes are some classes of bacteria that cause meningitis.
Nausea, vomiting, photophobia, and altered mental status are some
symptoms of meningitis. Immunization can help to prevent bacterial
meningitis.
Based on vaccine type, the global
meningitis vaccine market can be segmented into haemophilus influenza
type b vaccine, pneumococcal conjugate vaccine, pneumococcal
polysaccharide vaccine, meningococcal vaccine, and others. The
meningococcal vaccine segment is likely to expand at a significant pace
during the forecast period because meningococcal vaccine can protect
from four classes of bacteria that cause meningitis. The meningococcal
vaccine segment can be sub-classified into meningococcal conjugate
vaccines and serogroup B meningococcal vaccines. In terms of end-user,
meningitis vaccine market can be bifurcated into adults and children.
The children segment is expected to grow at a faster rate because
bacterial meningitis mostly affects children. In terms of distribution
channel, the global meningitis vaccine market can be segmented into
hospital pharmacies, retail pharmacies, and others. The hospital
pharmacies segment is likely to expand at a significant pace during the
forecast period as several types of vaccine are widely available in
hospital pharmacies.
Increase in incidence of meningitis in
children is one of the major factors fueling the global meningitis
vaccine market. Moreover, risk of permanent disabilities among children
and rise in awareness about proper dose of immunization is projected to
drive the meningitis vaccine market. However, bacterial resistance to
penicillin and lack of access to vaccine approval are likely to hamper
meningitis vaccine market in the next few years.
In terms of region, the global meningitis
vaccine market can be segmented into North America, Europe, Asia
Pacific, Latin America, and Middle East & Africa. North America
dominates the global meningitis vaccine market. The region is projected
to account for a significant share of the global meningitis vaccine
market during the forecast period due to presence of key vaccine
manufacturers and awareness about immunization. Favorable government
support in terms of inclusion of vaccination such as meningococcal C
conjugate (MCC) vaccine in national routine immunization schedules by
the European Center for Disease Prevention and Control to treat
meningitis is likely to drive the meningitis vaccine market in Europe.
Incidence of bacterial meningitis is increasing in countries such as
Thailand and North Korea. This drives demand for vaccination to combat
the disease which in turn is expected to propel meningitis vaccine
market in Asia Pacific. Increase in awareness about meningitis
immunization and high prevalence of bacterial meningitis are likely to
augment the meningitis vaccine market in Middle East & Africa during
the forecast period.
Key players operating in the global
meningitis vaccine market are GlaxoSmithKline, plc, Pfizer, Inc., Merck
& Co., Inc., Sanofi Pasteur SA, Astellas Pharma Inc., CSL Limited,
Emergent BioSolutions, Inc., Johnson & Johnson, MedImmune, LLC,
Serum Institute of India Pvt. Ltd., Bavarian Nordic, Mitsubishi Tanabe
Pharma Corporation, Protein Sciences Corporation, and Panacea Biotec,
among others.
No comments:
Post a Comment